Adma Biologics Inc 's ability to collect accounts receivable sequentially worsen to 3.58, pointing to a challenging and on top of that deteriorating business climate for the Biotechnology & Pharmaceuticals industry. Adma Biologics Inc 's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 102 days, from 97 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 452 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 2918, from overall ranking in the first quarter 2026 at 3294.

What is Receivable Turnover Ratio?
What is Adma Biologics Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ADMA Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	25.98 %	36.67 %	216.86 %	174.58 %	264.38 %
Y / Y Revenue Change	2.61 %	-0.3 %	18.39 %	11.67 %	13.88 %
Receivable Turnover Ratio (TTM)	3.58	3.75	4.02	4.9	6.11
ADMA's Total Ranking	# 2918	# 3294	# 2669	# 2272	# 1707
Accounts Receivable average collection period days	102	97	91	74	60
Seq. Receivable Change	1.74 %	-14.24 %	15.08 %	25.47 %	10.38 %
Seq. Revenue Change	9.36 %	-18.26 %	4.14 %	10.23 %	6.25 %

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 48
Healthcare Sector	# 453
Overall Market	# 2918

Receivable Turnover Ratio Statistics
High	Average	Low
21.9	9.18	3.58
(Dec 31 2013)		(Jun 30 2026)

ADMA Company Profile • Back to ADMA Efficiency Comparisons • Compare ADMA Receivables Turnover Ratio to its Competitors

Financial Statements
Adma Biologics Inc 's Accounts Receivable	$ 138 Millions	Visit ADMA's Balance sheet
Adma Biologics Inc 's Sales TTM	$ 511 Millions	Visit ADMA's Income Statement
Sources of ADMA's Revenues		Visit ADMA's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
ADMA's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
ADMA's Growth Rates	ADMA's Roa	ADMA's Inventory Turnover Ratio	ADMA's Dividend Comparisons
ADMA's Profitability Ratios	ADMA's Roi	ADMA's Asset Turnover Ratio	ADMA's Dividend Growth
ADMA's Valuation Ratios	ADMA's Roe	ADMA's Financial Strength Ratios	ADMA's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Kestra Medical Technologies Ltd	10.00	$ 105.939 Millions	$ 10.590 Millions
United Therapeutics Corporation	9.93	$ 3,154.500 Millions	$ 317.550 Millions
Utah Medical Products Inc	9.88	$ 35.679 Millions	$ 3.612 Millions
Biolife Solutions Inc	9.67	$ 102.718 Millions	$ 10.626 Millions
The Oncology Institute Inc	9.66	$ 587.244 Millions	$ 60.780 Millions
Sharps Technology Inc	9.65	$ 1.960 Millions	$ 0.203 Millions
Encompass Health Corporation	9.57	$ 6,206.100 Millions	$ 648.325 Millions
Septerna Inc	9.42	$ 98.882 Millions	$ 10.501 Millions
Biofrontera Inc	9.33	$ 45.956 Millions	$ 4.928 Millions
Enanta Pharmaceuticals Inc	9.29	$ 65.258 Millions	$ 7.027 Millions
The Pennant Group Inc	9.27	$ 1,101.710 Millions	$ 118.798 Millions
Crinetics Pharmaceuticals Inc	9.25	$ 42.156 Millions	$ 4.558 Millions
Neuronetics Inc	9.24	$ 154.594 Millions	$ 16.732 Millions
Myomo Inc	9.24	$ 44.242 Millions	$ 4.790 Millions
Harmony Biosciences Holdings inc	9.22	$ 960.191 Millions	$ 104.164 Millions
Bioaffinity Technologies Inc	9.18	$ 5.901 Millions	$ 0.643 Millions
Pavmed Inc	9.16	$ 0.126 Millions	$ 0.014 Millions
Clene Inc	9.16	$ 0.197 Millions	$ 0.022 Millions
Ardent Health Inc	9.16	$ 6,405.940 Millions	$ 699.363 Millions
Lexicon Pharmaceuticals Inc	9.14	$ 41.469 Millions	$ 4.535 Millions
Novavax inc	9.06	$ 413.796 Millions	$ 45.668 Millions
Nuvation Bio Inc	9.05	$ 169.551 Millions	$ 18.737 Millions
Cue Biopharma Inc	9.04	$ 37.654 Millions	$ 4.165 Millions
Sunshine Biopharma Inc	9.03	$ 35.347 Millions	$ 3.916 Millions
Biocryst Pharmaceuticals Inc	9.00	$ 940.613 Millions	$ 104.543 Millions
Edwards Lifesciences Corporation	8.99	$ 6,512.500 Millions	$ 724.750 Millions
Cannapharmarx Inc	8.86	$ 1.699 Millions	$ 0.192 Millions
Grail Inc	8.85	$ 165.263 Millions	$ 18.670 Millions
Guardant Health Inc	8.84	$ 1,183.105 Millions	$ 133.772 Millions
Zomedica Corp	8.84	$ 35.903 Millions	$ 4.063 Millions

Date modified: 2026-09-11T09:50:09+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.